The estimated Net Worth of James Fortune is at least $1.11 Million dollars as of 15 September 2015. James Fortune owns over 9,470 units of Ocular Therapeutix Inc stock worth over $945,786 and over the last 10 years James sold OCUL stock worth over $162,505.
James has made over 1 trades of the Ocular Therapeutix Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently James sold 9,470 units of OCUL stock worth $162,505 on 15 September 2015.
The largest trade James's ever made was selling 9,470 units of Ocular Therapeutix Inc stock on 15 September 2015 worth over $162,505. On average, James trades about 1,894 units every 0 days since 2015. As of 15 September 2015 James still owns at least 112,060 units of Ocular Therapeutix Inc stock.
You can see the complete history of James Fortune stock trades at the bottom of the page.
James's mailing address filed with the SEC is C/O OCULAR THERAPEUTIX, INC., 36 CROSBY DRIVE, SUITE 101, BEDFORD, MA, 01730.
Over the last 10 years, insiders at Ocular Therapeutix Inc have traded over $73,512,800 worth of Ocular Therapeutix Inc stock and bought 6,361,550 units worth $38,632,070 . The most active insiders traders include Management Inc. Opaleye, Road Llc Summer, and Venture Management Co. V, L.... On average, Ocular Therapeutix Inc executives and independent directors trade stock every 43 days with the average trade being worth of $999,228. The most recent stock trade was executed by Sanjay Nayak on 23 August 2024, trading 1,832 units of OCUL stock currently worth $16,525.
ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib
Ocular Therapeutix Inc executives and other stock owners filed with the SEC include: